Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) Stock On Radar After Q4 Earnings Update

March 17, 2023

Commercial stage biopharmaceutical company Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) is currently involved in the development of novel therapies meant for hepatitis delta virus and other similarly serious diseases. Yesterday, the company came into focus after it announced its financial results for the fourth fiscal quarter and the fiscal year, both of which ended on December 31, 2022. Trading Data On Thursday, EIGR stock decreased 0.85% to $1.1700 with more than 268.77K…